To study the efficacy of Tranexamic acid with Hemocoagulase in minimising cumulative axillary drain output in breast cancer patients undergoing axillary lymph node dissection- double blinded superiority trial. - HEXA

开始日期2022-04-09

申办/合作机构-

CTRI/2022/03/041433 / Not yet recruitingN/AIIT

Comparison of local application of hemocoagulase solution and saline pressure pack in wound healing and incidence of dry socket after extraction of mandible first and second molars

开始日期2022-03-29

申办/合作机构-

CTRI/2020/11/029267 / Recruiting临床4期IIT

Effectiveness of hemocoagulase on the healing of surgical wounds in the neck- a randomized clinical trial

开始日期2020-11-25

申办/合作机构-

100 项与白眉蛇毒血凝酶相关的临床结果

登录后查看更多信息

100 项与白眉蛇毒血凝酶相关的转化医学

登录后查看更多信息

100 项与白眉蛇毒血凝酶相关的专利（医药）

登录后查看更多信息

项与白眉蛇毒血凝酶相关的文献（医药）

2024-06-01·World Journal of Surgery

Efficacy of perioperative systemic tranexamic acid along with topical hemocoagulase in decreasing axillary drain output in breast cancer patients undergoing axillary lymph node dissection: A randomized, double‐blind, placebo‐controlled, superiority trial

Article

作者: Sinha, Upasna ; Pandey, Jagjit Kumar ; Jha, Chandan Kumar ; Verma, Harshit ; Singh, Prashant Kumar ; Kumar, Manoj ; Ahmad, Shamshad

AbstractBackgroundExcess and prolonged axillary drainage is a frequent nuisance following axillary lymph node dissection (ALND) in breast cancer patients. No consensus exists about the best method to prevent this consistently and reliably. Tranexamic acid (TA) has been found to reduce the amount and duration of drainage, but the reduction is not optimal. We hypothesized that systemic administration of TA along with the topical application of hemocoagulase (H) to the axillary dissection bed may decrease the cumulative axillary drain output and shorten the requirement of drainage after ALND as compared to placebo.Patient and MethodsSeventy women undergoing ALND for breast carcinoma were randomized into two groups, the intervention (TA + H) group and the control (C) group. The cumulative drain output (primary objective), duration of drainage, incidence of seroma formation after drain removal, number of seroma aspirations required, volume of seroma aspirated, and incidence of surgical site infection (SSI) were compared.ResultsThe mean cumulative output in the TA + H group was significantly lower than the C group (290 ± 200 mL vs. 552 ± 369 mL, p < 0.001). Axillary drains were removed significantly earlier in the TA + H group (6.6 ± 2.2 vs. 11.7 ± 6.0 days, p < 0.001), but the incidence of seroma formation (p = 0.34), number of aspirations required (p = 0.33), volume of seroma aspirated (p = 0.47), and the incidence of SSI (p = 0.07) were similar.ConclusionsPerioperative systemic administration of tranexamic acid along with topical application of H to the axillary dissection bed is effective in reducing cumulative axillary drain output after ALND. This strategy may also facilitate earlier removal of suction drains.

2023-12-01·Acta Orthopaedica Belgica

Effectiveness and safeties of hemocoagulase and tranexamic acid to reduce perioperative blood loss in intertrochanteric fracture PFNA fixation

Article

作者: Wang, L ; Wang, C ; Zhang, D ; Wang, W ; Wang, F

This study evaluated the efficacy of hemocoagulase and tranexamic acid (TXA) in minimizing perioperative blood loss in perioperative period of proximal femoral nail antirotation (PFNA) repair. 99 patients having intertrochanteric fracture PFNA fixation were randomly assigned to the hemocoagulase, TXA, and control groups (n=33 per group). In the hemocoagulase group, 1 KU of hemocoagulase was injected preoperatively and postoperatively local sprayed, respectively; in the TXA group, 0.5g TXA was injected preoperatively and postoperatively local sprayed, respectively; and in the control group, 100 mL of physiological saline was injected before surgery and was used by postoperative local spraying, respectively. The hemocoagulase and TXA groups exhibited significant differences in preoperative hemoglobin (HB) and hematocrit (HCT) levels on postoperative days 1 and 3, intraoperative bleeding, 24-hour postoperative drainage, total perioperative bleeding, transfusion rate, and postoperative hospitalization duration compared to the control group. Furthermore, the hemocoagulase and TXA groups showed significant differences in postoperative day 3 HB and HCT levels and postoperative hospitalization duration compared to each other. In conclusions, the combined use of systemic preoperative and local postoperative hemocoagulase and TXA spraying is found to significantly decrease perioperative blood loss in intertrochanteric fracture patients undergoing PFNA. Hemocoagulase is observed to have a superior effect compared to TXA.

2023-08-31·Journal of the Korean Association of Oral and Maxillofacial Surgeons

Effectiveness of hemocoagulase, tranexamic acid, and their combination for reducing blood loss in bimaxillary orthognathic surgery: a retrospective study.

Article

作者: Han, Se-Jin ; Kim, Min-Soo

ObjectivesOrthognathic surgery is a corrective intervention for maxillofacial deformities. Bleeding is a major concern for oral and maxillofacial surgeons. Various agents, such as hemocoagulase, tranexamic acid, and aprotinin have been developed to reduce intraoperative bleeding and transfusion requirements. Therefore, in this study we aimed to investigate the effects of hemocoagulase and tranexamic acid, as well as their simultaneous use, to reduce bleeding during orthognathic surgery. Patients and.MethodsThis retrospective study included patients who had undergone simultaneous orthognathic surgery of the maxilla and mandible between January 2013 and September 2022 and were classified into three groups based on drugs administered: hemocoagulase (Botropase), tranexamic acid, and a combination of both drugs. We recorded patient age, sex, weight, blood loss, and duration of surgery. Red blood cell (RBC), hemoglobin, hematocrit, and platelet levels were measured before, immediately after, and one day after surgery.ResultsNo statistically significant differences were found in blood loss, RBC, hemoglobin, hematocrit, or platelet levels between any of the groups. There were no differences in the drug effects between Le Fort I and bilateral mandibular sagittal split osteotomies, with or without double genioplasty. However, there were significant reductions in RBC, hemoglobin, hematocrit, and platelet levels during genioplasty.ConclusionTranexamic acid, hemocoagulase, and their combination had similar efficacy in patients who underwent Le Fort Ⅰ and bilateral mandibular sagittal split osteotomies with and without genioplasty.

项与白眉蛇毒血凝酶相关的新闻（医药）

2024-03-22

·米内网

【重磅】中药1类新药报喜！190亿市场风云再起

精彩内容3月21日，康辰药业公告称，中药1.2类创新药金草片Ⅲ期临床试验已达到主要研究终点，用于治疗盆腔炎性疾病后遗症慢性盆腔痛。米内网数据显示，2022年中国三大终端六大市场妇科中成药销售额超过190亿元。金草片是首个以“盆腔炎性疾病后遗症慢性盆腔痛”适应症开发的中药1.2类创新药品种，主要成分为“总环烯醚萜苷”，从单一中药筋骨草全草中提取的有效部位制备而成，物质基础明确、作用机制清晰。目前国内尚无治疗盆腔炎性疾病后遗症慢性盆腔痛的药物获批。Ⅲ期临床试验统计分析结果表明，金草片在为期12周治疗期内VAS评分的疼痛消失率达到主要研究终点；金草片的安全性和耐受性良好，不良事件发生率低。康辰药业将择机就金草片治疗盆腔炎性疾病后遗症慢性盆腔痛的上市申请与监管部门进行沟通。米内网数据显示，妇科中成药2022年在中国三大终端六大市场（统计范围见文末）销售额超过190亿元，尚未恢复至疫情之前水平，2023年上半年销售额接近100亿元。从细分终端上看，公立医院终端（城市公立医院+县级公立医院）为妇科中成药的“主战场”，2022年占据超60%的市场份额。中国三大终端六大市场妇科中成药销售情况（单位：万元）来源：米内网格局数据库2018年至今国内已有4款妇科中药创新药获批上市，包括通化万通药业的关黄母颗粒、奇绩医药的金蓉颗粒、天士力的坤心宁颗粒、湖南安邦制药的芪胶调经颗粒。据不完全统计，目前国内已有25款妇科中药新药处于获批临床及以上阶段，涉及康缘药业、天士力、盈科瑞、白云山中一药业等知名中药企业。康辰药业创立于2003年，公司的注射用尖吻蝮蛇血凝酶（商品名：苏灵）是目前国内血凝酶制剂市场唯一国家1类创新药。2023年前三季度公司研发费用6721.90万元，同比增长22.87%。目前康辰药业有2款1类创新药在研，化药1类创新药KC1036片已处于Ⅲ期临床阶段，用于治疗食管鳞癌；中药1.2类创新药金草片Ⅲ期临床试验成功，预计成为公司首款获批上市的中药1类创新药。资料来源：米内网数据库、公司公告注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

临床3期信使RNA

2022-12-03

·药闻康策

这批未过评药品带量采购结果公布了!

点击上方一键预约最新最热的医药健康新闻政策11 月 29 日晚，江苏省医保局公布了江苏省第三轮药品集中带量采购的拟中选结果，并进行公示，简要信息如下：#药品名称申报企业1氟比洛芬凝胶贴膏北京泰德制药2注射用洛铂海南长安国际制药3注射用矛头蝮蛇血凝酶蓬莱诺康药业4桉柠蒎肠溶胶囊北京远大九和药业5桉柠蒎肠溶胶囊北京远大九和药业6多烯磷脂酰胆碱胶囊赛诺菲7注射用白眉蛇毒血凝酶锦州奥鸿药业8蛇毒血凝酶注射液兆科药业9整蛋白型肠内营养剂国药集团药业10复方甲氧那明胶囊长兴制药11盐酸丙卡特罗颗粒黑龙江龙德药业12榄香烯口服乳液大连华立金港药业13肠内营养乳剂（TP-HE）费卡华瑞14洛芬待因缓释片西南药业15注射用醋酸亮丙瑞林缓释微球北京博恩特药业16胞磷胆碱钠胶囊齐鲁制药17胞磷胆碱钠片四川梓橦宫药业18门冬氨酸钾注射液苏州特瑞药业19门冬氨酸钾注射液内蒙古白医制药20门冬氨酸钾注射液辽宁药联制药21奥沙利铂甘露醇注射液江苏恒瑞医药22奥沙利铂甘露醇注射液辰欣药业23奥沙利铂甘露醇注射液四川美大康佳乐药业24洛索洛芬钠贴剂上海朝晖药业25美沙拉秦栓广州医药26甲硝唑凝胶天津市天骄制药27复方聚乙二醇电解质散（Ⅰ）江西恒康药业28复方聚乙二醇电解质散（Ⅱ）深圳万和制药29注射用头孢匹胺钠山东鲁抗医药30注射用头孢匹胺广州白云山天心制药31门冬氨酸鸟氨酸注射液湖南赛隆药业32门冬氨酸鸟氨酸注射液青岛金峰制药33复方消化酶胶囊广东鼎信医药科技34复方消化酶胶囊(Ⅱ)常州千红生化制药35甘露醇注射液山东威高药业36甘露醇注射液江苏正大丰海制药37甘露醇注射液石家庄四药38甘露醇注射液蚌埠丰原涂山制药39甘露醇注射液安徽双鹤药业40甘露醇注射液四川科伦药业41甘露醇注射液成都倍特药业42甘露醇注射液辽宁海神联盛制药43甘露醇注射液天津金耀集团湖北天药药业44甘露醇注射液河北天成药业45甘露醇注射液福州海王福药制药46甘露醇注射液广东雷允上药业47维生素C注射液瑞阳制药48维生素C注射液山东新华制药49维生素C注射液天津金耀药业50维生素C注射液辰欣药业51维生素C注射液河南润弘制药52维生素C注射液山东益康药业53维生素C注射液石药集团欧意药业54维生素C注射液安徽联谊药业55维生素C注射液河南天致药业56维生素C注射液成都倍特药业57维生素C注射液广东邦民制药厂58注射用维生素C哈尔滨三联药业59维生素C注射液信合援生制药60注射用维生素C山西振东泰盛制药61维生素C注射液山东圣鲁制药62注射用维生素C陕西博森生物制药63盐酸消旋山莨菪碱注射液杭州民生药业64盐酸消旋山莨菪碱注射液上海现代哈森药业65盐酸消旋山莨菪碱注射液山西晋新双鹤药业66盐酸消旋山莨菪碱注射液甘肃兰药药业67碳酸氢钠注射液江苏正大丰海制药68碳酸氢钠注射液石家庄四药69碳酸氢钠注射液河北天成药业70碳酸氢钠注射液四川科伦药业71碳酸氢钠注射液回音必集团江西东亚制药72碳酸氢钠注射液湖南康源制药73碳酸氢钠注射液上海华源安徽锦辉制药74碳酸氢钠注射液浙江天瑞药业75碳酸氢钠注射液上海锦帝九州药业76碳酸氢钠注射液四川美大康华康药业77碳酸氢钠注射液国药集团容生制药78碳酸氢钠注射液石药银湖制药79碳酸氢钠注射液上海浦津林州制药80注射用磷酸川芎嗪苏州二叶制药81磷酸川芎嗪注射液山东新华制药82注射用盐酸川芎嗪北京四环科宝制药83注射用磷酸川芎嗪福建省闽东力捷迅药业84注射用盐酸川芎嗪平光制药85盐酸川芎嗪注射液成都倍特药业86盐酸川芎嗪注射液西安汉丰药业87注射用磷酸川芎嗪海南葫芦娃药业集团88注射用磷酸川芎嗪瑞阳制药89注射用磷酸川芎嗪晋城海斯制药90注射用曲克芦丁海南倍特药业91维生素B6注射液山西太原药业92维生素B6注射液河南润弘制药93维生素B6注射液天津金耀集团湖北天药药业94维生素B6注射液国药集团容生制药95维生素B6注射液上海现代哈森药业96维生素B6注射液常州制药厂97维生素B6注射液马鞍山丰原制药98维生素B6注射液西安风华药业99盐酸伐昔洛韦片珠海润都制药100盐酸伐昔洛韦片山东罗欣药业集团101盐酸伐昔洛韦分散片辰欣药业102盐酸伐昔洛韦分散片湖北科益药业103注射用奥扎格雷钠湖南恒生制药104注射用奥扎格雷钠哈药集团生物工程105注射用奥扎格雷钠山东罗欣药业集团106注射用奥扎格雷钠北京赛升药业107注射用奥扎格雷钠哈尔滨三联药业108奥扎格雷钠注射液河南天致药业109注射用奥扎格雷钠海南倍特药业110注射用奥扎格雷钠长春雷允上药业111注射用奥扎格雷钠浙江金华康恩贝生物制药112奥扎格雷钠注射液海南碧凯药业113氨甲苯酸注射液扬州中宝药业114氨甲苯酸注射液郑州卓峰制药115氨甲苯酸注射液辅仁药业集团116氨甲苯酸注射液山东圣鲁制药117氨甲苯酸注射液上海浦津林州制药118氨甲苯酸注射液瑞阳制药119氨甲苯酸注射液安徽联谊药业120注射用氨甲苯酸山东北大高科华泰制药121氨甲苯酸注射液上海现代哈森药业122氨甲苯酸注射液甘肃兰药药业123氨甲苯酸注射液安徽长江药业124氨甲苯酸注射液武汉久安药业125氨甲苯酸注射液湖北科伦药业126氨甲苯酸注射液武汉爱民制药127氨甲苯酸注射液西安利君制药128氨甲苯酸注射液宜昌人福药业129氨甲苯酸注射液山东齐都药业130乳酸钠林格注射液山东威高药业131乳酸钠林格注射液浙江天瑞药业132乳酸钠林格注射液四川太平洋药业133乳酸钠林格注射液石家庄四药134乳酸钠林格注射液安徽双鹤药业135丁酸氢化可的松乳膏湖北恒安芙林药业136丁酸氢化可的松乳膏天津太平洋制药137利巴韦林注射液天津金耀集团湖北天药药业138利巴韦林注射液郑州卓峰制药139利巴韦林注射液瑞阳制药140利巴韦林注射液国药集团容生制药141利巴韦林注射液江苏涟水制药142利巴韦林注射液上海现代哈森药业143利巴韦林注射液河南润弘制药144利巴韦林注射液山西太原药业145利巴韦林注射液马鞍山丰原制药146利巴韦林注射液华润双鹤利民药业147利巴韦林注射液安徽联谊药业148利巴韦林注射液湖北科伦药业149利巴韦林注射液成都倍特药业150利巴韦林注射液河南天致药业151利巴韦林注射液北京双鹭药业152利巴韦林注射液广州白云山明兴制药153利巴韦林注射液山东益健药业154利巴韦林注射液山西国润制药155利巴韦林注射液武汉久安药业156利巴韦林注射液青岛金峰制药157利巴韦林注射液西安利君制药158泛昔洛韦片丽珠集团丽珠制药厂159泛昔洛韦片山东罗欣药业集团160泛昔洛韦分散片浙江永宁药业161泛昔洛韦分散片山东海山药业162注射用阿洛西林钠海口奇力制药163注射用阿洛西林钠四川制药制剂11 月 10 日，江苏省医保局宣布开展第三轮药品带量采购，通过对江苏省药品（医用耗材）阳光采购和综合监管平台已挂网且截至公告发布前一日未通过（含视同通过）质量和疗效一致性评价药品采购数据的梳理，经专家论证，筛选确定江苏省第三轮药品带量采购的 43 个品种。本次带量采购对独家品种和非独家品种的报价及给量有不同的要求，从中选结果来看，独家品种应该基本保持全国最低价中选，没有继续梯度降价要量，非独家品种则应该又有了进一步的降价以求中选。（来源:医药代表）药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购申请上市

100 项与白眉蛇毒血凝酶相关的药物交易

登录后查看更多信息